Of note, mogamulizumab treatment has also shown to efficiently deplete Treg cells in patients with ATLL and CTCLs [173] and to increase tumor-specific CD8+ T cells in the blood of patients with ATLL [174,202]. This evidence concerns the gene CD8A and neoplasm.